1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Cardiometabolic Drug News FEBRUARY 2015

Cardiometabolic Drug News FEBRUARY 2015

  • February 2015
  • -
  • Espicom Business Intelligence
  • -
  • 13 pages

Industry Trend Analysis - Afrezza's US Launch Will Test Appetite For New Insulin Delivery Systems
Industry Brief - Merck Repatriates Diabetes/Thyroids Portfolio In Russia
Industry Brief - Hua Raises Funds To Start Phase II Trials
Industry Brief - FDA Approves First-In-Class Glyxambi For Adults With Type II Diabetes
Industry Brief - FDA Approves Savaysa For NVAF/VTE
Industry Brief - Daiichi Sankyo Pays USD39mn To Settle Kickback Allegations
Industry Brief - CHMP Adopts Positive Opinion On Saxenda For Obesity
Industry Brief - FDA Approves Symplmed's Prestalia For Hypertension
Industry Brief - Novo Nordisk Launches Xultophy In Switzerland
Industry Brief - Milestone Triggered As Belviq Approved In South Korea For Weight Management
Industry Brief - Praluent MAA Accepted For Review By EMA
Industry Brief - Elite Commences Isradipine Shipments
Industry Brief - FDA Accepts Praluent BLA For Priority Review
Industry Brief - NICE Recommends Jardiance For Type II Diabetes
Industry Brief - CHMP Issues Positive Opinions For Kengrexal/Orbactiv/Raplixa
Industry Brief - NICE Recommends Xarelto For Reducing Risk Of Secondary Events In ACS
Industry Brief - Bydureon Pre-Filled Pen Available In UK For Type II Diabetes
Industry Brief - Positive Results Reported From First Phase III Trials Of Alirocumab
Industry Brief - Vericel Completes Enrolment In Phase IIb ixCELL-DCM Study Of Ixmyelocel-T
Industry Brief - Oramed Granted Patent In Israel Covering Exenatide
Industry Brief - FDA Removes PPAR Partial Clinical Hold On Esperion's ETC-1002
Industry Brief - Isis Reports Data From Phase II Study Of ISIS-PTP1BRx In Type II Diabetes
Industry Brief - Milestone Receives FDA Clearance Of MSP-2017 Phase II IND
Industry Brief - Brilinta Meets Primary Endpoint With 60/90mg Doses In ACS Study
Industry Brief - Phase III Study Of Andexanet Alfa/Xarelto Meets Primary Endpoint

Table Of Contents

Cardiometabolic Drug News FEBRUARY 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...

Global Markets for Diabetes Therapeutics and Diagnostics

Global Markets for Diabetes Therapeutics and Diagnostics

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Analyze the market for drugs used in the treatment of diabetes, it's technology and the industry as a whole - Identify important trends and provide sales forecasts by product categories ...

Personal Mobility Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023

Personal Mobility Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023

  • $ 5795
  • Industry report
  • August 2016
  • by Transparency Market Research

Personal mobility devices such as wheelchairs, mobility scooters, and stair lifts have witnessed significant growth in revenue and volume in the past few years. A personal mobility device is either a manual ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.